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Decreased clinical response to
adalimumab in ankylosing
spondylitis is associated with
antibody formation
Treatment with anti-tumour necrosis factor (TNF) is very
effective in most patients with ankylosing spondylitis (AS), but
inefficacy occurs in about 40% of cases.1 Antibody formation
against TNF blocking agents is an increasingly recognised
problem;2 however, no data have yet been reported on antibody
formation against adalimumab (anti-adalimumab) in AS. Lack
of response can be explained in two ways: (1) TNF might not be
important for disease activity in certain patients; and (2) TNF
inhibition might be insufficient. The latter could be caused by
excessive production of TNF, low compliance of the patient,
insufficient dosing or an enhanced clearance of adalimumab due
to antibody formation. Adalimumab is a fully human mono-
clonal antibody against TNF but, despite this fact, an immune
response still can be provoked by the antigen binding site also
known as the idiotype. In previous studies we have described
the problem of immunogenicity of TNF blocking drugs in
patients with rheumatoid arthritis (RA),3 in patients with AS
treated with infliximab4 and in patients with RA treated with
adalimumab,5 and concluded that the presence of antibodies
against infliximab or adalimumab was associated with low or
undetectable serum levels of infliximab or adalimumab and
clinical non-response.
The objective of the present study was to investigate the
relation between the formation of anti-adalimumab, serum
adalimumab levels and clinical response in AS.
Patients with AS6 were treated with adalimumab, 40 mg
every other week, according to the international ASAS
consensus statement.7 8 Clinical response was defined as a
50% improvement or an absolute improvement of 2 points on
the BASDAI scale (0–10). Serum samples were collected at
baseline and after 3 and 6 months of treatment. Serum
adalimumab levels were determined with an ELISA and anti-
adalimumab was measured with a validated antigen binding
test. The assays used were similar to those described previously
for the detection of infliximab levels and antibodies against
infliximab.4 5
Thirty-five patients were included. After 6 months of
treatment, 18 were ASAS responders (table 1). Within 6 months
of treatment, 11 patients developed anti-adalimumab with low
or undetectable adalimumab levels, 9 were ASAS non-respon-
ders (p = 0.012) and 1 had an allergic reaction with flushing,
dyspnoea and undetectable serum adalimumab levels (fig 1).
Thus, anti-adalimumab was detected in 31% of the patients
after 6 months of treatment and this corresponded with
diminished or undetectable serum adalimumab levels in these
patients. These preliminary observations will need confirmation
in a larger study. In contrast with the treatment of RA,
adalimumab is given without methotrexate in the treatment of
AS. This might be an explanation for the higher incidence of
anti-adalimumab formation in AS. In Crohn’s disease and in
RA, the concomitant use of immunosuppressive drugs or
corticosteroids has been proved to decrease antibody formation
against infliximab.9 10
To date, no other papers have reported on immunogenicity in
the treatment of AS with adalimumab and no systemic allergic
reactions have been described. The detection of antibodies
might predict the inefficacy of adalimumab and should be
explored further for use in daily clinical practice.
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Table 1 Baseline characteristics and clinical variables
Baseline
(N = 35) t = 6 months
Male gender, n (%) 27 (76)
Mean (SD) age (years) 43 (12)
Disease duration (years) 9 (3.5–16.5)
HLA-B27 positive, n (%) 24 (69)
Presence of IBD, n (%) 4 (12)
Presence of uveitis, n (%) 15 (46)
Presence of arthritis, n (%) 11 (32)
Anti-TNF used before, n (%) 10 (29)
BASDAI 6.2 (4.9–7.6) 3.0 (1.2–5.3)*
ASAS response (N responders, %) 18 (51%)
Global disease activity 7.2 (5.9–8.0) 2.1 (1.0–5.0)*
ESR 31 (19–44) 7 (3–15)*
CRP 21 (10–35) ,5 (2–6)*
Unless otherwise indicated, values are median (interquartile range).
ASAS, Assessments in Ankylosing Spondylitis (decrease of 50% or .2, global disease
activity (0–10 scale)); BASDAI, Bath Ankylosing Spondylitis Disease Activity Index (0–
10 scale); CRP, C-reactive protein (normal ,10.0 mg/l); ESR, erythrocyte sedimentation
rate (normal ,15 mm/h); HLA B27, human leucocyte antigen B27; IBD, inflammatory
bowel disease.
*p,0.001 compared with baseline.
Figure 1 Relation between the presence of anti-adalimumab and
response of ankylosing spondylitis to treatment with adalimumab.
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MRSA infections in patients treated
with tumour necrosis factor
inhibitors
Clinical experience with the three available tumour necrosis
factor (TNF) inhibitors (etanercept, infliximab and adalimu-
mab) shows improvement in inflammatory arthritis. Clinical
studies have reported serious infections such as reactivation
tuberculosis following treatment with TNF inhibitors. Bacterial
infections with organisms such as Staphylococcus aureus (both
methicillin-sensitive (MSSA) and methicillin-resistant (MRSA)),
Streptococcus and Gram-negative organisms have not been
reported to be more frequent or severe. We noticed several
severe MRSA infections in patients treated with TNF inhibitors
and wondered whether these agents might alter the outcome of
these infections. We therefore performed a retrospective
analysis of patients treated in our practice.
Between August 2003 and July 2006, 430 patients with
inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis
and ankylosing spondylitis) were treated with anti-TNF agents
in our practice. In all instances where infections occurred,
bacterial culture results were documented, patients were
interviewed and examined and all pertinent hospital and
medical records were reviewed. Institutional review board
approval for a retrospective chart review was obtained through
the Anne Arundel Medical Center (LICJ-0501(E)).
As indicated in table 1, there were 15 severe MRSA infections
and 11 severe MSSA infections. The most common infection in
both was cellulites. Other infections included osteomyelitis,
pneumonia, sinusitis and septic arthritis. There was one case of
Fournier’s gangrene with MRSA sepsis and one of mastitis. Over
half the infections occurred within the first 6 months of
treatment. Infections occurred with all TNF agents: infliximab
(9), etanercept (10) and adalimumab (6). One patient was a
known MRSA carrier.
The average age of the patients was 61 years; 59% were
women and 41% were men. Concomitant diseases included
diabetes (7), coronary disease (6) and renal insufficiency (3).
Prednisone (20) and methotrexate (10) were concomitant
treatments in many of these patients.
Most infections were severe and required hospitalisation.
Twelve patients with MRSA were hospitalised; 14 required
intravenous antibiotics. Seven patients with MSSA were
hospitalised; nine required intravenous antibiotics.
Attempts to restart TNF inhibitors after control of MRSA
infection resulted in recurrent MRSA infection in seven
patients. Two patients were able to resume TNF inhibitor
therapy after the infection was controlled. Two patients were
treated with rituxan with no recurrences.
Other infections included Gram-negative bacterial cellulites
(4), severe Clostridium difficile infections (3) and tuberculosis
infection with fatal pneumonia (1). Seventeen other patients
had pneumonia (6), diverticulitis (2) and cellulites (9) with no
bacterial agent cultured.
In this study, MRSA and MSSA infections were more
frequent than any other infection and were more severe than
expected. Our patient population was older and had more
concomitant diseases such as diabetes than in previous
publications. We do not know the MRSA carrier status of most
of our patients before initiating treatment with TNF inhibitors.
We do know that retreatment of known carriers resulted in
recrudescence of MRSA infections in seven patients.
In the USA approximately one-third of patients carry MSSA
and 0.8% of patients carry MRSA.1 2 A significant number of
patients receiving treatment with TNF inhibitors may be at risk
for activation of infection.3 4
Several questions arise about treatment with TNF inhibitors:
c Should known MRSA carriers be treated with TNF agents?
c Should patients be treated with TNF agents once the
infection has subsided?
Table 1 MRSA and MSSA infections in 25 patients treated with anti-
TNF agents
Organism
MRSA
(n = 15)
MSSA
(n = 10)
Cellulitis 6 5
Osteomyelitis 3 1
Pneumonia 1 –
Sinusitis 2 –
Septic arthritis 1 4
Mastitis 1 –
Fournier’s gangrene 1 –
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive
Staphylococcus aureus; TNF, tumour necrosis factor.
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